Tonix Pharmaceuticals Holding (TNXP) Short term Debt (2011 - 2024)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Short term Debt came in at $2.8 million in Q4 2024, up 20.0% year-on-year from $2.4 million in Q1 2024, and little changed quarter-over-quarter from $2.8 million in Q3 2024.
Tonix Pharmaceuticals Holding (TNXP) Short term Debt (2011 - 2024) Analysis & Trends
Tonix Pharmaceuticals Holding's Short term Debt history runs 3 years deep, the most recent figure standing at $2.8 million for Q4 2024.
- On a quarterly basis, Short term Debt rose 20.0% year-over-year to $2.8 million in Q4 2024; TTM through Dec 2024 was $2.8 million, a 20.0% increase from a year earlier, with the FY2024 full-year figure at $2.8 million, up 20.0% from the prior year.
- Short term Debt steadied at $2.8 million in Q4 2024 per TNXP's latest filing, from $2.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $2.8 million in Q1 2024 and bottomed at $2.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Tonix Pharmaceuticals Holding | 141.73 Mn | 141.73 Mn | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 2.82 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 2.82 Mn |
| Dec 31, 2023 | 2.35 Mn |
| Dec 31, 2011 | 150,000.00 |
| Sep 30, 2011 | 10,000.00 |